These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 8852331

  • 1. Protein kinase inhibitors--potential chemotherapeutic agents.
    Shugar D.
    Acta Biochim Pol; 1995; 42(4):405-18. PubMed ID: 8852331
    [Abstract] [Full Text] [Related]

  • 2. Development of inhibitors of protein kinases CKI and CKII and some related aspects, including donor and acceptor specificities and viral protein kinases.
    Shugar D.
    Cell Mol Biol Res; 1994; 40(5-6):411-9. PubMed ID: 7735315
    [Abstract] [Full Text] [Related]

  • 3. The NTP phosphate donor in kinase reactions: is ATP a monopolist?
    Shugar D.
    Acta Biochim Pol; 1996; 43(1):9-23. PubMed ID: 8790708
    [Abstract] [Full Text] [Related]

  • 4. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets.
    Legraverend M, Grierson DS.
    Bioorg Med Chem; 2006 Jun 15; 14(12):3987-4006. PubMed ID: 16503144
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.
    J Pharm Belg; 1997 Jun 15; 52(2):88-96. PubMed ID: 9193132
    [Abstract] [Full Text] [Related]

  • 6. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME, Endicott JA, Johnson LN.
    Science; 2004 Mar 19; 303(5665):1800-5. PubMed ID: 15031492
    [Abstract] [Full Text] [Related]

  • 7. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A, Schwartz GK.
    Cancer J; 2000 Mar 19; 6(4):192-212. PubMed ID: 11038138
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM.
    Circulation; 2004 Mar 16; 109(10):1196-205. PubMed ID: 15023894
    [Abstract] [Full Text] [Related]

  • 9. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
    Kirkland LO, McInnes C.
    Biochem Pharmacol; 2009 May 15; 77(10):1561-71. PubMed ID: 19167366
    [Abstract] [Full Text] [Related]

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 15; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 11. Non-nucleoside inhibitors of herpesviruses.
    Wathen MW.
    Rev Med Virol; 2002 Aug 15; 12(3):167-78. PubMed ID: 11987142
    [Abstract] [Full Text] [Related]

  • 12. Rational design of polymerase inhibitors as antiviral drugs.
    Oberg B.
    Antiviral Res; 2006 Sep 15; 71(2-3):90-5. PubMed ID: 16820225
    [Abstract] [Full Text] [Related]

  • 13. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T.
    Chem Biol Drug Des; 2006 Jan 15; 67(1):46-57. PubMed ID: 16492148
    [Abstract] [Full Text] [Related]

  • 14. Development of Src tyrosine kinase substrate binding site inhibitors.
    Ye G, Tiwari R, Parang K.
    Curr Opin Investig Drugs; 2008 Jun 15; 9(6):605-13. PubMed ID: 18516760
    [Abstract] [Full Text] [Related]

  • 15. Are MAP kinases drug targets? Yes, but difficult ones.
    Margutti S, Laufer SA.
    ChemMedChem; 2007 Aug 15; 2(8):1116-40. PubMed ID: 17541990
    [Abstract] [Full Text] [Related]

  • 16. Targeting protein kinases in cancer therapy.
    Fabbro D, García-Echeverría C.
    Curr Opin Drug Discov Devel; 2002 Sep 15; 5(5):701-12. PubMed ID: 12630290
    [Abstract] [Full Text] [Related]

  • 17. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ.
    Oncogene; 2000 Dec 27; 19(56):6574-83. PubMed ID: 11426642
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
    Laufer SA, Domeyer DM, Scior TR, Albrecht W, Hauser DR.
    J Med Chem; 2005 Feb 10; 48(3):710-22. PubMed ID: 15689155
    [Abstract] [Full Text] [Related]

  • 19. dUTP pyrophosphatase as a potential target for chemotherapeutic drug development.
    McIntosh EM, Haynes RH.
    Acta Biochim Pol; 1997 Feb 10; 44(2):159-71. PubMed ID: 9360704
    [Abstract] [Full Text] [Related]

  • 20. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
    Wang Y, Shakespeare WC, Huang WS, Sundaramoorthi R, Lentini S, Das S, Liu S, Banda G, Wen D, Zhu X, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Dalgarno D, Clackson T, Sawyer TK.
    Bioorg Med Chem Lett; 2008 Sep 01; 18(17):4907-12. PubMed ID: 18691885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.